№

Name of the project, IRN, full name of the head

Deadlines

Funding

organization

Type of financing,

priority areas

1

2

3

4

5

School of Pharmacy

1.    

IRN AP22686038 «Development of technology for the production and standardization of cardiotonic profile extracts». Head: Orynbekova S.O.

2024-2026

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

2.    

IRN АР19680441 «Pharmaceutical development and pharmacological research of dental films for use in dental practice». Head: Datkhaev U.M.

2023-2025

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

3.       

IRN АР19679386 «Development of a thermoregulated transdermal patch with antibacterial and anti-inflammatory action». Head: Begimova G.U.

2023-2025

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

4.       

IRN AP14971256 «Pharmaceutical development of a gel with analgesic and anti-inflammatory action from the plant Portulaca oleracea (Portulaca oleracea L.)». Head: Tleubaeva M.I.

2022-2024

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

5.       

Chemical development and research of active pharmaceutical substances based on nitrogen-containing heterocyclic compounds. Head: Berillo A.D.

2022-2024

S.Asfendiyarov KazNMU 

6.       

Development of a conceptual project for the creation and production of medical and preventive products based on Morus Alba L. Head: Zhakipbekov K.S.

2022-2024

S.Asfendiyarov KazNMU 

7.       

Development of a full production cycle of antiseptic products based on natural raw materials. Head: Kozhanova K.K.

2022-2024

S.Asfendiyarov KazNMU 

8.       

Pharmaceutical development and experimental substantiation of the use of antifungal agents for the treatment of pathology of the organ of vision. Head: Ustenova G.O.

2023-2025

S.Asfendiyarov KazNMU 

9.       

Phytochemical study of squat Euphorbia (Euphorbia humifusa Willd.) and the development of a herbal pharmaceutical substance. Head: Zhakipbekov K.S.

2023-2024

S.Asfendiyarov KazNMU 

10.   

Development of technology and standardization of the herbal pharmaceutical substance kuzinia teneva Soysia umbrosa Bunge. Head: Makhatova B.G.

2023-2024

S.Asfendiyarov KazNMU 

School of General Medicine 1

11.   

IRN AP22684163 «Development of new bactericidal biocomposites based on biopolymers with silver nanoparticles stabilized with plant extracts with a fast-acting wound healing effect». Head: Kalieva A.M.

2022-2024

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

12.   

IRN AP22786227 «Identification of immune, genetic and microbiological biomarkers of bronchopulmonary dysplasia». Head: Abilbaeva A.A.

2022-2024

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

13.   

IRN AP14972665 «Mechanisms of impaired inflammation regulation under the influence of chemical ecotoxicants and new ways of their pathogenetic treatment». Head: Kairanbayeva G.K.

2022-2024

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

14.   

The prognostic role of the tumor microenvironment in the directional manipulation of components of the immune system during acute pneumonia and the development of new methods of pathogenetic correction. Head: Balabekova M.K.

2023-2025

S.Asfendiyarov KazNMU 

15.   

Determination of viral and bacterial associations in acute sinusitis in children and their phagotyping. Head: Koloskova K.K.

2023-2024

S.Asfendiyarov KazNMU 

School of General Medicine 2

16.   

IRN АР19679719 «Improvement of nuclear medicine imaging for malignant tumors by the implementation of innovative technologies of hybrid imaging». Head: Zholdybai Zh.Zh.

2023-2025

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

17.   

IRN АР19676226 «Study of genetic markers and environmental factors in phakomatoses and neurogenic tumors». Head: Idrisova Zh.R.

2023-2025

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

18.   

IRN AP14870557 «The study of respiratory, cardiovascular and metabolic disorders after a new coronavirus infection COVID-19». Head: Sugraliev A.B.

2022-2024

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

19.   

Assessment of the psychosomatic state and improvement of rehabilitation methods for CHF patients who have suffered covid infection in PHC conditions. Head: Tazhieva A.E.

2022-2024

S.Asfendiyarov KazNMU 

20.   

Implementation of a system of diagnosis, treatment and rehabilitation for certain orphan diseases with neurological manifestations in children. Head: Idrisova Zh.R.

2022-2024

S.Asfendiyarov KazNMU 

School of Pediatrics

21.   

Development of diagnostic, therapeutic and preventive measures in newborns with congenital heart defects born to mothers with COVID-19. Head: Bozhbanbayeva N.S.

2022-2024

S.Asfendiyarov KazNMU 

22.   

New methods of forecasting, prevention and correction of necrotic enterocolitis in premature infants. Head: Baigazieva G.Zh.

2022-2024

S.Asfendiyarov KazNMU 

School of Dentistry

23.   

IRN AP22686056 «The use of innovative non-invasive methods for the prevention and treatment of caries in children with autism». Head: Serikbayeva Zh.U.

2023-2025

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health

24.   

Development of an innovative strategy for dental prosthetics using digital technologies. Head: Altynbekov K.D.

2023-2024

S.Asfendiyarov KazNMU 

Faculty of Postgraduate Education

25.   

Assessment of predictors of the ineffectiveness of antiviral therapy for chronic hepatitis C in the Republic of Kazakhstan. Head: Nersesov A.V.

2022-2023

S.Asfendiyarov KazNMU 

26.   

Clinical and immunological characteristics and evaluation of predictors of immunosuppressive therapy in patients with autoimmune hepatitis in the Republic of Kazakhstan. Head: Nersesov A.V.

2023-2025

S.Asfendiyarov KazNMU 

B. Atchabarov Scientific Research Institute of Fundamental and Applied Medicine

27.   

IRN АР19680286 «Development and introduction of the national register of patients with familial hypercholesterolemia in Kazakhstan». Head: Davletov K.K.

2023-2025

(36 months)

MSНЕ RK

Grant funding,

Life Science and Health